Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on June 15, 2017. The filing discloses the appointment of a new named executive officer and the entry into a material definitive employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
On June 15, 2017, the Company appointed Nitya Ray, Ph.D., as Executive Vice President, Head of Product Development, Manufacturing, and Supply Chain. Dr. Ray joins from CytoDyn, Inc., bringing 15 years of prior experience at Progenics Pharmaceuticals, Inc., as well as experience at Hoffman-La Roche and Verax Corporation.
Guidance, Outlook, and Management Commentary
The filing details the compensatory arrangements for Dr. Ray, effective May 26, 2017:
- Base Salary: $325,000 per year.
- Cash Bonus: Target of 30% of base salary, amount determined by the Board.
- Equity Grant: Option to purchase 250,000 common shares at the closing price on June 15, 2017.
- Vesting Schedule: 28% vests 12 months after the grant date; the remainder vests at 2% per month thereafter. Options have a 10-year term.
- Restrictive Covenants: Includes a 3-year non-competition clause regarding radioimmunotherapies for cancer and bone marrow transplant therapies, and a 24-month non-solicitation clause for employees and consultants.
The full Employment Agreement is scheduled to be included as an exhibit to the Form 10-Q for the quarter ending June 30, 2017.
Investor Verification Checklist
- Verify the closing stock price on June 15, 2017, to determine the exercise price of the 250,000 options granted.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2017, for the full text of the Employment Agreement.
- Assess the impact of the 3-year non-competition clause on the Company's ability to hire from competitors in the radioimmunotherapy space.
- Confirm Dr. Ray's start date and integration timeline into the manufacturing and supply chain operations.